Early evidence suggests US Food and Drug Administration Commissioner nominee Martin Makary could be a more “conventional” agency leader than others in President Trump’s second administration.
US FDA Under Makary: MAHA With A Lighter Touch
US FDA Commissioner nominee Martin Makary is being embraced by industry, and Senate Democrats, as a more traditional pick than other Trump Administration nominees, but the Make America Healthy Again agenda still is clearly coming to the agency.
More from Leadership
More from HBW Insight
• By
Ibis Reproductive Health adds Desiree Williams to lead MORE Study; Radicle Science adds Rob Sinnott as senior strategic advisor; Leann Sims joins AbundaBox as COO; former Cannabis Beverage Association president moves to Vertosa; Vegamour expands executive staff with CMO; and Oura Ring firm appoints CMO.
• By
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
• By
Single-use packaging producers subject to California’s SB 54 recycling law, which implements a statewide EPR plan, should continue to prepare for its implementation, even as they enter a ‘prolonged period of uncertainty,’ says consultant Michael Washburn.